<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856263/" ref="ordinalpos=4764&amp;ncbi_uid=2871014&amp;link_uid=PMC2856263" image-link="/pmc/articles/PMC2856263/figure/F6/" class="imagepopup">FIGURE 6. From: Activation of the Nucleotide Oligomerization Domain <span class="highlight" style="background-color:">Signaling</span> <span class="highlight" style="background-color:">Pathway</span> by the Non-bacterially Derived Xanthone Drug 5?6-Dimethylxanthenone-4-acetic Acid (Vadimezan). </a></div><br /><div class="p4l_captionBody"><b>Schematic diagram of signaling pathways activated by DMXAA.</b> Previous work (13) has shown that DMXAA can activate TANK-binding kinase 1 to initiate IRF3 signaling. Our data indicate that DMXAA also activates NOD-like receptors NOD2 and NOD1 that interact with RICK to activate NF-ÎºB signal pathways that regulate production of inflammatory cytokines/chemokines.</div></div>